Share
   
Title
Code
Session Type
Venue
Date Time
Organizer:

Oral Truvada is the only agent approved for pre-exposure prophylaxis (PrEP); however, adherence to a daily regimen remains a challenge. As such, optimizing current regimens, identifying new PrEP agents and adding new routes of administration remain a priority. Several studies are evaluating methods to optimize adherence to daily oral Truvada. The safety and efficacy of new agents, including oral Maraviroc and injectable rilpivirine/cabotegravir, are being evaluated in MSM and women. Other anti-viral drugs are being developed as implants, which, if successful, will have the advantage of administering long-acting agents every 6 months with the added benefit of removal for safety or when no longer needed. At the cutting edge of HIV prevention are monoclonal antibodies. Two studies evaluating the infusion of them are underway. If successful, these studies will demonstrate proof of concept, making way for other monoclonal antibodies. Any of these options could be game changers for HIV prevention.

07:00
MOSA0201
Welcome
Wafaa El-Sadr, United States
07:05
MOSA0202
Overview of the Field of Systemic PrEP
Myron Cohen, United States
Slides
07:25
MOSA0203
Monoclonal Antibodies for HIV Prevention
Nyaradzo Mavis Mgodi, Zimbabwe
Slides
07:45
MOSA0204
Next Generation Drugs and Delivery for PrEP
Thomas John Hope, United States
Slides
08:05
MOSA0205
Optimizing Delivery of Oral PrEP
Connie Celum, United States
Slides
08:25
MOSA0206
Questions